Effect of doxycycline in patients of moderate to severe chronic obstructive pulmonary disease with stable symptoms

Annals of Thoracic Medicine

Volumn 6, Issue 4, 2011, Pages 221-226

  Dalvi, Prashant S ^a   Singh, Anil ^a   Trivedi, Hiren R ^a   Ghanchi, Feroz D ^a   Parmar, Dinesh M ^a   Mistry, Suresh D ^a  

^a M P SHAH MEDICAL COLLEGE   (India)

Author keywords

Anti inflammatory; C reactive protein; doxycycline; dyspnea; matrix metalloproteinase; respiratory function tests

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CORTICOSTEROID; DOXYCYCLINE; IPRATROPIUM BROMIDE; MATRIX METALLOPROTEINASE; SALBUTAMOL; THEOPHYLLINE;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ASSESSMENT; COMPETITIVE INHIBITION; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DYSPNEA; FORCED EXPIRATORY VOLUME; HUMAN; INTERVENTION STUDY; LUNG FUNCTION; MAJOR CLINICAL STUDY; METERED DOSE INHALER; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SMOKING; SYMPTOM; TREATMENT DURATION;

EID: 80052899871     PISSN: 18171737     EISSN: 19983557     Source Type: Journal    
DOI: 10.4103/1817-1737.84777     Document Type: Article

References (34)

1. Global Initiative for chronic obstructive lung disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease-2009. Available from: http:/www.goldcopd.com [Last accessed on 2010 Oct 15].
2. Belvisi MG, Bottomley KM. The role of matrix metalloproteinases (MMPs) in the pathophysiology of chronic obstructive pulmonary disease (COPD): A therapeutic role for inhibitors of MMPs? Inflamm Res 2003;52:95-100. (Pubitemid 36470068)
3. Reilly (Jr.) JJ Silverman EK, Shapiro SD. Chronic Obstructive Pulmonary Disease. In: Casper DL, Braunwald E editors. Harrison's Principles of Internal Medicine. New York: McGraw-Hill; 2006. p. 1547-54.
4. Betsuyaku T, Nishimura M, Takeyabu K, Tanino M, Venge P, Xu S, et al. Neutrophil granule proteins in bronchoalveolar lavage fluid from subjects with subclinical emphysema. Am J Respir Crit Care Med 1999;159:1985-91 (Pubitemid 29275073)
5. Finlay GA, Russell KJ, McMahon KJ, D'arcy EM, Masterson JB, FitzGerald MX, et al0. Elevated levels of matrix metalloproteinases in bronchoalveolar lavage fluid of emphysematous patients. Thorax 1997;52:502-6. (Pubitemid 27298499)
6. Golub LM, Suomalainen K, Sorsa T. Host modulation with tetracyclines and their chemically modified analogues. Curr Opin Dent 1992;2:80-90.
7. Suomalainen K, Sorsa T, Golub LM, Ramamurthy N, Lee HM, Uitto VJ, et al. Specificity of the anticollagenase action of tetracyclines: Relevance to their anti-inflammatory potential. Antimicrob Agents Chemother 1992;36:227-9.
8. Fiotti N, Altamura N, Moretti M, Wassermann S, Zacchigna S, Farra R, et al. Short term effects of doxycycline on matrix metalloproteinases 2 and 9. Cardiovasc Drugs Ther 2009;23:153-9.
9. Zhao S, Choksuchat C, Zhao Y, Ballagh SA, Kovalevsky GA, Archer DF. Effects of doxycycline on serum and endometrial levels of MMP-2, MMP-9 and TIMP-1 in women using a levonorgestrel-releasing subcutaneous implant. Contraception 2009;79:469-78.
10. Sochor M, Richter S, Schmidt A, Hempel S, Hopt UT, Keck T. Inhibition of matrix metalloproteinase-9 with doxycycline reduces pancreatitis-associated lung injury. Digestion 2009;80:65-73.
11. Doroszko A, Hurst TS, Polewicz D, Sawicka J, Fert-Bober J, Johnson DH, et al. Effects of MMP-9 inhibition by doxycycline on proteome of lungs in high tidal volume mechanical ventilation-induced acute lung injury. Proteome Sci 2010;8:3.
12. Raza M, Ballering JG, Hayden JM, Robbins RA, Hoyt JC. Doxycycline decreases monocyte chemoattractant protein-1 in human lung epithelial cells. Exp Lung Res 2006;32:15-26. (Pubitemid 43732304)
13. Sapadin AN, Fleischmajer R. Tetracyclines: Nonantibiotic properties and their clinical implication. J Am Acad Dermatol 2006;54:258-64.
14. Nordström D, Lindy O, Lauhio A, Sorsa T, Santavirta S, Konttinen YT. Anti-collagenolytic mechanism of action of doxycycline treatment in rheumatoid arthritis. Rheumatol Int 1998;17:175-80. (Pubitemid 28122001)
15. Ciancio S, Ashley R. Safety and efficacy of sub-antimicrobial dose doxycycline therapy in patients with adult periodontitis. Adv Dent Res 1998;12:27-37.
16. Skidmore R, Kovach R, Walker C, Thomas J, Bradshaw M, Leyden J, et al. Effects of subantimicrobial-dose doxycycline in the treatment of moderate acne. Arch Dermatol 2003;139:459-64. (Pubitemid 36427610)
17. Skulason S, Holbrook WP, Kristmundsdottir T. Clinical assessment of the effect of a matrix metalloproteinase inhibitor on aphthous ulcers. Acta Odontol Scand 2009;67:25-9.
18. Dursun D, Kim MC, Soloman A, Pflugfelder SC. Treatment of recalcitrant corneal erosions inhibitors of matrix metalloproteinase-9, doxycycline and corticosteroids. Am J Ophthalmol 2001;132:8-13. (Pubitemid 32600883)
19. Smieja M, MacPherson DW, Kean W, Schmuck ML, Goldsmith CH, Buchanan W, et al. Randomised, blinded, placebo controlled trial of doxycycline for chronic seronegative arthritis. Ann Rheum Dis 2001;60:1088-94. (Pubitemid 33096072)
20. Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987;106:196-204. (Pubitemid 17009877)
21. Cazzola M, MacNee W, Martinez FJ, Rabe KF, Franciosi LG, Barnes PJ, et al. Outcomes for COPD pharmacological trials: From lung function to biomarkers. Eur Respir J 2008;31:416-69.
22. Seemungal TA, Donaldson GC, Bhowmik A, Jeffries DJ, Wedzicha JA. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;161:1608-13. (Pubitemid 30329036)
23. Stockley RA, O'Brien C, Pye A, Hill SL. Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. Chest 2000;117:1638-45. (Pubitemid 30413357)
24. Koivunen AL, Maisi P, Konttinen YT, Prikk K, Sandholm M. Collagenolytic activity and its sensitivity to doxycycline inhibition in tracheal aspirates of horses with chronic obstructive pulmonary disease. Acta Vet Scand 1997;38:9-16. (Pubitemid 127515786)
25. Maugban T, Peterson-Short K, Truax C, Lee S, Kenyon N, Liou TG. Doxycycline improves decline in pulmonary function in OB/BOS. J Heart Lung Transplant 2009;28: S281-2.
26. Bhattacharyya P, Nag S, Ghosh D, Roy-Chowdhury S, Bardhan S, Mukherjee A. Treatment of probable idiopathic pulmonary fibrosis with long term doxycycline, a matrix metalloproteinase inhibitor. Indian J Chest Dis Allied Sci 2007;49:180.
27. Brown DL, Desai KK, Vakili BA, Nouneh C, Lee HM, Golub LM. Clinical and biochemical results of the metalloproteinase inhibition with subantimicrobial doses of doxycycline to prevent acute coronary syndromes (MIDAS) pilot trial. Arterioscler Thromb Vasc Biol 2004:24;733-8. (Pubitemid 38451612)
28. Michel G, Mosser J, Olle J. Pharmacokinetics and tissue localization of doxycycline polyphosphate and doxycycline hydrochloride in the rat. Eur J Drug Metab Pharmacokinet 1984;9:149-53. (Pubitemid 14077553)
29. Pepys MB, Hirschfield GM. C-reactive protein: A critical update. J Clin Invest 2003;111:1805-12. (Pubitemid 38057722)
30. Dahl M, Vestbo J, Lange P, Bojesen SE, Tybjaerg-Hansen A, Nordestgaard BG. C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;175:250-5. (Pubitemid 46203128)
31. Man P, Connett JE, Anthonisen NR, Wise RA, Tashkin DP, Sin DD. C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease. Thorax 2006;61:849-53. (Pubitemid 44570304)
32. Sin DD, Lacy P, York E, Man SF. Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004;170:760-5. (Pubitemid 39298991)
33. Hajiro T, Nishimura K, Tsukino M, Ikeda A, Koyama H, Izumi T. Analysis of clinical methods used to evaluate dyspnea in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;158:1185-9. (Pubitemid 28489021)
34. Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax 1999;54:581-6. (Pubitemid 29296676)